We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches.
- Authors
Ruehs, Hauke; Solms, Alexander; Frei, Matthias; Becker, Corina; Trujillo, Maria E.; Garmann, Dirk; Meyer, Michaela
- Abstract
Background and Objectives: Vericiguat is a soluble guanylate cyclase stimulator indicated to reduce the risk of cardiovascular death and hospitalization due to heart failure. A dedicated QTc study in patients with chronic coronary syndromes demonstrated no clinically relevant QTc effect of vericiguat for exposures across the therapeutic dose range (2.5–10 mg). Interval prolongation concentration-QTc (C-QTc) modeling was performed to complement the statistical evaluations of QTc in the dedicated QTc study. Methods: Individual time-matched, baseline- and placebo-corrected Fridericia-corrected QT interval values (ΔΔQTcF) were derived. Two approaches for ΔΔQTcF calculation were investigated: (1) ΔΔQTcF correction with data from a single baseline (as in the primary statistical analysis); and (2) ΔΔQTcF correction with a modeled baseline (considering all available individual non-treatment baselines). The ΔΔQTcF values were related to observed vericiguat concentrations with linear mixed-effects modeling. Results: For both modeling approaches, a positive relationship was found between ΔΔQTcF and vericiguat concentration; however, the slope for the single-baseline approach was not statistically significant, whereas the slope from the modeled-baseline approach was statistically significant. The upper bound of the two-sided 90% confidence interval for model-derived QTc was < 10 ms at the highest observed exposure (745 μg/L; investigated dose range 2.5–10 mg). Conclusion: By applying a single-baseline approach and a modeled-baseline approach that integrated all available QTc data across doses to characterize the QTc prolongation potential, this study showed that vericiguat 2.5–10 mg is not associated with clinically relevant QTc effects, in line with the conclusion from the primary statistical analysis. Clinical Trials Registration Number: ClinicalTrials.gov NCT03504982.
- Subjects
CLINICAL trial registries; GUANYLATE cyclase; CARDIOVASCULAR disease related mortality; HEART failure; CARDIOVASCULAR diseases risk factors
- Publication
Clinical Pharmacokinetics, 2023, Vol 62, Issue 11, p1639
- ISSN
0312-5963
- Publication type
Article
- DOI
10.1007/s40262-023-01282-y